Connect Biopharma (CNTB) IPO Opens 15% Higher

Today's IPO for Connect Biopharma Holdings Limited (NASDAQ: CNTB) opened for trading at $19.55 after pricing 11,250,000 ADSs, representing 11,250,000 ordinary shares of the Company, at a public offering price of US$17.00 per ADS.

Jefferies LLC, SVB Leerink LLC, Piper Sandler & Co. and China International Capital Corporation Hong Kong Securities Limited are acting as joint book-running managers for this offering.

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research.

Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Our second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).

You May Also Be Interested In

• Standard Nuclear launches IPO roadshow targeting up to $21 per share
• Rivian Automotive Inc (RIVN) PT Raised to $17 at Jefferies
• Exyn Technologies reports Q1 2026 results after Nasdaq IPO